Sichuan Kelun Pharmaceutical Co., Ltd. (002422.SZ)
CNY 34.85
(-0.99%)
CNY 34.85
(-0.99%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 2.45 Billion CNY | 44.03% |
| 2022 | 1.7 Billion CNY | 96.44% |
| 2021 | 868.11 Million CNY | 4.67% |
| 2020 | 829.38 Million CNY | -11.57% |
| 2019 | 937.85 Million CNY | -22.68% |
| 2018 | 1.21 Billion CNY | 62.04% |
| 2017 | 748.54 Million CNY | 28.04% |
| 2016 | 584.63 Million CNY | -9.4% |
| 2015 | 645.27 Million CNY | -35.6% |
| 2014 | 1 Billion CNY | -7.19% |
| 2013 | 1.07 Billion CNY | -0.74% |
| 2012 | 1.08 Billion CNY | 12.56% |
| 2011 | 966.12 Million CNY | 46.11% |
| 2010 | 661.22 Million CNY | 54.55% |
| 2009 | 427.85 Million CNY | 38.07% |
| 2008 | 309.88 Million CNY | 43.28% |
| 2007 | 216.28 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 514.3 Million CNY | -49.88% |
| 2024 Q1 | 1.02 Billion CNY | 108.24% |
| 2024 Q3 | 670.81 Million CNY | 30.43% |
| 2023 Q1 | 814.45 Million CNY | 173.54% |
| 2023 Q4 | 492.78 Million CNY | -12.18% |
| 2023 FY | 2.45 Billion CNY | 44.03% |
| 2023 Q3 | 561.12 Million CNY | -5.2% |
| 2023 Q2 | 591.88 Million CNY | -27.33% |
| 2022 Q1 | 291.37 Million CNY | 14.6% |
| 2022 Q4 | 297.74 Million CNY | -45.15% |
| 2022 FY | 1.7 Billion CNY | 96.44% |
| 2022 Q3 | 542.87 Million CNY | -5.87% |
| 2022 Q2 | 576.7 Million CNY | 97.93% |
| 2021 Q1 | 175.43 Million CNY | -46.5% |
| 2021 Q3 | 355.47 Million CNY | 12.0% |
| 2021 Q4 | 254.26 Million CNY | -28.47% |
| 2021 Q2 | 317.37 Million CNY | 80.91% |
| 2021 FY | 868.11 Million CNY | 4.67% |
| 2020 FY | 829.38 Million CNY | -11.57% |
| 2020 Q2 | 180.95 Million CNY | 726.67% |
| 2020 Q4 | 327.92 Million CNY | 9.81% |
| 2020 Q3 | 298.62 Million CNY | 65.03% |
| 2020 Q1 | 21.88 Million CNY | -7.19% |
| 2019 Q3 | 186 Million CNY | -52.62% |
| 2019 Q1 | 335.68 Million CNY | 77.08% |
| 2019 Q2 | 392.57 Million CNY | 16.95% |
| 2019 FY | 937.85 Million CNY | -22.68% |
| 2019 Q4 | 23.58 Million CNY | -87.32% |
| 2018 Q1 | 383.19 Million CNY | 5.83% |
| 2018 Q4 | 189.56 Million CNY | -23.98% |
| 2018 Q3 | 249.35 Million CNY | -36.2% |
| 2018 FY | 1.21 Billion CNY | 62.04% |
| 2018 Q2 | 390.82 Million CNY | 1.99% |
| 2017 Q2 | 63.5 Million CNY | -67.04% |
| 2017 FY | 748.54 Million CNY | 28.04% |
| 2017 Q4 | 362.07 Million CNY | 177.84% |
| 2017 Q3 | 130.31 Million CNY | 105.22% |
| 2017 Q1 | 192.64 Million CNY | 308.52% |
| 2016 Q4 | 47.15 Million CNY | -68.86% |
| 2016 FY | 584.63 Million CNY | -9.4% |
| 2016 Q1 | 208.21 Million CNY | 119.94% |
| 2016 Q2 | 177.85 Million CNY | -14.58% |
| 2016 Q3 | 151.41 Million CNY | -14.87% |
| 2015 Q4 | 94.66 Million CNY | -33.03% |
| 2015 FY | 645.27 Million CNY | -35.6% |
| 2015 Q3 | 141.35 Million CNY | -30.49% |
| 2015 Q2 | 203.34 Million CNY | -1.24% |
| 2015 Q1 | 205.9 Million CNY | 16.89% |
| 2014 Q3 | 288.87 Million CNY | -6.5% |
| 2014 Q1 | 227.92 Million CNY | -1.23% |
| 2014 FY | 1 Billion CNY | -7.19% |
| 2014 Q4 | 176.15 Million CNY | -39.02% |
| 2014 Q2 | 308.95 Million CNY | 35.55% |
| 2013 Q2 | 327.73 Million CNY | 58.62% |
| 2013 Q3 | 314.4 Million CNY | -4.07% |
| 2013 FY | 1.07 Billion CNY | -0.74% |
| 2013 Q4 | 230.75 Million CNY | -26.61% |
| 2013 Q1 | 206.61 Million CNY | -35.58% |
| 2012 Q3 | 304.89 Million CNY | 4.33% |
| 2012 Q1 | 169.62 Million CNY | -39.13% |
| 2012 Q4 | 320.75 Million CNY | 5.2% |
| 2012 Q2 | 292.24 Million CNY | 72.3% |
| 2012 FY | 1.08 Billion CNY | 12.56% |
| 2011 Q1 | 147.37 Million CNY | -29.62% |
| 2011 FY | 966.12 Million CNY | 46.11% |
| 2011 Q4 | 278.67 Million CNY | 0.57% |
| 2011 Q3 | 277.08 Million CNY | 5.36% |
| 2011 Q2 | 262.99 Million CNY | 78.45% |
| 2010 Q3 | 191.6 Million CNY | 14.69% |
| 2010 Q2 | 167.07 Million CNY | 79.37% |
| 2010 Q1 | 93.14 Million CNY | -33.76% |
| 2010 Q4 | 209.4 Million CNY | 9.29% |
| 2010 FY | 661.22 Million CNY | 54.55% |
| 2009 Q4 | 140.61 Million CNY | 18.37% |
| 2009 FY | 427.85 Million CNY | 38.07% |
| 2009 Q3 | 118.79 Million CNY | 15.42% |
| 2009 Q2 | 102.92 Million CNY | 57.08% |
| 2009 Q1 | 65.52 Million CNY | 0.0% |
| 2008 FY | 309.88 Million CNY | 43.28% |
| 2007 FY | 216.28 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Zhejiang Int'l Group Co.,Ltd. | 488.73 Million CNY | -402.548% |
| Zhejiang Zhenyuan Share Co., Ltd. | 81.64 Million CNY | -2908.372% |
| Hunan Jingfeng Pharmaceutical Co.,Ltd. | -215.14 Million CNY | 1241.613% |
| Hubei Guangji Pharmaceutical Co., Ltd. | -140.24 Million CNY | 1851.263% |
| Yifan Pharmaceutical Co., Ltd. | -551.07 Million CNY | 545.696% |
| Guangdong Jiaying Pharmaceutical Co., Ltd | 34.32 Million CNY | -7056.455% |
| Chongqing Lummy Pharmaceutical Co., Ltd. | -8.92 Million CNY | 27612.286% |
| Boai NKY Medical Holdings Ltd. | 493.02 Million CNY | -398.17% |
| Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. | 310.18 Million CNY | -691.822% |